(Q68194420)

English

Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary

scientific article published on 01 January 1987

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

phase III clinical trial

1 reference

based on heuristic

inferred from title

transitional cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Maru

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

H Akaza

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

S Isaka

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

K Koiso

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

T Kotake

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

T Machida

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Y Matsumura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Y Nakagami

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

T Niijima

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

K Obata

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

publication date

1 January 1987

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

20 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

S44-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy of Bladder Carcinoma with Cyclophosphamide and Adriamycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The management of advanced bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cis-diamminedichloroplatinum II in advanced urothelial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of advanced carcinoma of the bladder with combination chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chemotherapy of urologic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of adriamycin in human neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The chemotherapy of advanced bladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy for advanced carcinoma of the bladder

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate in the Treatment of Metastatic and Recurrent Primary Transitional Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined chemotherapy in the management of metastatic bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A study of cyclophosphamide, adriamycin, cis-platinum, and methotrexate in advanced transitional cell carcinoma of the urinary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/3311445

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00262484

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:3311445%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q68194420&oldid=2218489128"